Uric Acid Lowering Trial in Youth Onset T2D
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT Number: NCT02200666
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga)
* Development of ADRs specified as Key Investigation Items and the risk factors * Contributing factors possibly having an impact on the safety and efficacy * Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use
Looking for future studies?
Notify MeAll sexes
Observational
Research Site, Aichi, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients treated with Forxiga for the first time due to type 2 diabetes mellitus, which is the indication of the drug.
Exclusion criteria
N/A
Time frame: from baseline to 3 years
AstraZeneca
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT04255433
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial DetailsNCT03887936
Diabetes Mellitus, Diabetes Mellitus, Type 2
Houston, Texas, United States
View Trial DetailsNCT02251431
Cardiovascular Diseases, Chronic Disease
Dallas, Texas, United States
View Trial Details